The LYCRA Company Showcases Denim Innovations at Kingpins New York
18.7.2022 12:00:00 EEST | Business Wire | Press release
The LYCRA Company, a global leader in developing innovative and sustainable fiber and technology solutions for the apparel and personal care industries, is exhibiting its latest products for denim in person at Kingpins New York July 20-21 at Pier 36 in New York City. The company is showcasing samples made with LYCRA® ADAPTIV fiber, LYCRA® DUAL COMFORT technology, and its other industry-leading denim fibers.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220718005067/en/
The LYCRA Company showcases denim innovations at Kingpins NYC. (Photo: Business Wire)
LYCRA® ADAPTIV fiber is a patent-pending revolutionary fiber that creates "one-size-fits-more" garments that adapt to fit different body shapes within a size. It also delivers a second-skin effect with excellent recovery and comfortable holding power.
"Consumers have different body types and this can impact garment fit and comfort," said Rita Ratskoff, senior strategic manager - denim, The LYCRA Company. "By offering greater shape tolerance, LYCRA® ADAPTIV fiber has the potential to reduce apparel returns and manufacturing waste by enabling the undercutting of patterns."
LYCRA® DUAL COMFORT technology combines the comfortable fit of stretch fabrics, the cool and dry comfort of moisture management, and LYCRA® T400® A EcoMade fiber, made from 68% sustainable resources including recycled and renewable content.
In The LYCRA Company booth, show visitors can also find innovative denim solutions from the LYCRA® XTRA LIFE™ brand's family of innovative denim solutions, including LYCRA® Anti-Slip fiber, LYCRA® dualFX® technology, and LYCRA® T400® fiber. They create long-lasting, durable garments that enable designers to develop heavy wash downs and distressed looks without fear.
For garment makers seeking sustainable offerings that reduce waste, denim that uses recycled materials will be on display. LYCRA® EcoMade fiber contains 20 percent recycled content, and COOLMAX® and THERMOLITE® EcoMade technologies are made from 100% textile waste.
"The LYCRA Company is committed to developing an innovative range of sustainable solutions made with renewable and recycled content that will enhance the performance of our customers' offerings while minimizing their environmental impact," said Jean Hegedus, sustainability director, The LYCRA Company. "We are excited to be in person at Kingpins again to promote our sustainable denim fibers that help reduce waste and set the stage for circularity."
Hegedus will join a panel discussion at Kingpins on July 21 at 11:30 a.m. entitled, "In Conversation: Denim Changemakers." This panel brings together representatives from companies in the United Nations Conscious Fashion and Lifestyle Network, whose members are accelerating change in the denim sector. Participants will discuss industry commitments to increase sustainable practices and advance collective action to reach the United Nations' Sustainable Development Goals.
Kingpins New York is an invitation-only event for the denim community at Pier 36 / Basketball City in Manhattan. For more information, visit kingpinsshow.com/shows/new-york/.
About The LYCRA Company
The LYCRA Company innovates and produces fiber and technology solutions for the apparel and personal care industries. Headquartered in Wilmington, Delaware, The LYCRA Company is recognized worldwide for its innovative products, technical expertise, sustainable solutions, and unmatched marketing support. The LYCRA Company owns leading consumer and trade brands: LYCRA®, LYCRA HyFit®, LYCRA® T400®, COOLMAX®, THERMOLITE®, ELASPAN®, SUPPLEX®, and TACTEL®. The LYCRA Company’s legacy stretches back to 1958 with the invention of the original spandex yarn, LYCRA® fiber. Today, The LYCRA Company focuses on adding value to its customers’ products by developing unique innovations designed to meet the consumer’s need for comfort and lasting performance. For more information, visit www.thelycracompany.com.
LYCRA®, dualFX®, T400®, XTRA LIFE™, COOLMAX® and THERMOLITE® are trademarks of The LYCRA Company.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220718005067/en/
Contact information
Kristin Altimari
kristin.altimari@lycra.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Datroway ® Approved in the EU as Only TROP2 Directed Medicine with Overall Survival Benefit for the First-Line Treatment of Patients with Metastatic TNBC Who Are Not Candidates for Immunotherapy31.7.2026 09:30:00 EEST | Press release
Datroway® (datopotamab deruxtecan) has been approved in the European Union (EU) as monotherapy for the first-line treatment of adult patients with unresectable or metastatic triple negative breast cancer (TNBC) who are not candidates for PD-1/PD-L1 inhibitor therapy. Datroway is a specifically engineered TROP2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The approval by the European Commission follows the positive opinionof the Committee for Medicinal Products for Human Use of the European Medicines Agency and is based on results from the TROPION-Breast02phase 3 trial, which were presented at the 2025 European Society for Medical Oncology Congress and subsequently published in Annals of Oncology. In TROPION-Breast02, which included patients with metastatic TNBC who experienced early relapse following prior treatment, Datroway demonstrated a statis
Polpharma Biologics Announces FDA and EMA Acceptance for Review of PB016 Vedolizumab Biosimilar Candidate31.7.2026 09:30:00 EEST | Press release
Polpharma Biologics International AG today announces that the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) have accepted for review the Biologics License Application (BLA) and Marketing Authorisation Application (MAA), respectively, for PB016, a proposed vedolizumab biosimilar candidate to Takeda’s reference product Entyvio®* (vedolizumab) lyophilized vial for intravenous (IV) administration for the treatment of adults with moderately to severely active ulcerative colitis and Crohn's disease. The BLA and MAA acceptances represent significant milestones in Polpharma Biologics' development program and underscore the company's commitment to advancing high-quality biosimilars and expanding global access to affordable biologic medicines. "FDA and EMA acceptances for review of our IV vedolizumab biosimilar candidate mark a major achievement for Polpharma Biologics and validate our deep scientific expertise in biosimilar development and manufacturing," said
Half-Year Report on SES’s Liquidity Contract31.7.2026 08:30:00 EEST | Press release
Pursuant to the liquidity contract entered into by SES with BNP Paribas as of 7 April 2026, please see the below update on the progress of the liquidity services. When the liquidity services were implemented as of 7 April 2026, the following assets were in the liquidity account: € 2,500,000 As of 30 June 2026, the following assets appeared on the liquidity account: 228,186 shares; € 816,880. Over the period from 7 April 2026 to 30 June 2026, the following transactions were executed: 1,082 buy transactions; 1,308 sales transactions. Over this same period, the volumes traded represented: 1,093,335 shares and € 8,485,986 on the buy side; 873,399 shares and € 6,860,843 on the sell side. Follow us on: LinkedIn | Facebook | YouTube | X | Instagram Read our Blogs > Visit the Media Gallery > About SES At SES, we believe that space has the power to make a difference. That’s why we design space solutions that help governments protect, businesses grow, and people stay connected—no matter where th
SES: Disclosure of Share Buyback Transactions31.7.2026 08:30:00 EEST | Press release
In the time period from June 2, 2026 until and including June 23, 2026, a number of 213,167 shares were bought back within the framework of the share buyback of SES to meet obligations under SES’s Equity Based Compensation Plan (EBCP). Shares were bought back as follows: Day of purchase Aggregated volume in shares Daily weighted average acquisition price of shares (EUR) Market June 2, 2026 27,097 8.8727 DXE June 2, 2026 72,903 8.8556 ENX June 5, 2026 16,624 8.3723 DXE June 5, 2026 31,510 8.4266 ENX June 15, 2026 26,451 7.8423 XPAR June 17, 2026 26,812 7.3910 XPAR June 23, 2026 11,770 7.2200 XPAR The transactions in a detailed form are published on SES’s website: https://www.ses.com/investors/shareholder-information/share-buy-backs. Follow us on: Twitter | Facebook | YouTube | LinkedIn | Instagram Read our Blogs > Visit the Media Gallery > About SES At SES, we believe that space has the power to make a difference. That’s why we design space solutions that help governments protect, busin
SES Publishes FY2025 EU Taxonomy Restatement31.7.2026 08:30:00 EEST | Press release
SES today published a restatement of its FY2025 EU Taxonomy (Article 8) disclosure. The restatement updates the FY2025 EU Taxonomy disclosure included in the 2025 Annual Report and supersedes the previously published disclosure. The FY2025 EU Taxonomy Restatement is available on the SES website: https://www.ses.com/sites/ses_v2/files/investor-files/2026-07/EU_Taxonomy_Report_Restatement_2025.pdf Follow us on: X | Facebook | YouTube | LinkedIn | Instagram Read our Blogs > Visit the Media Gallery > About SES At SES, we believe that space has the power to make a difference. That’s why we design space solutions that help governments protect, businesses grow, and people stay connected—no matter where they are. With integrated multi-orbit satellites and our global terrestrial network, we deliver resilient, seamless connectivity and the highest quality video content to those shaping what’s next. Following our Intelsat acquisition, we now offer more than 100 years of combined global industry l
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom